Last reviewed · How we verify
Tamsulosine Arrow LP
Tamsulosin is an alpha-1A adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow.
Tamsulosin is an alpha-1A adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow. Used for Benign prostatic hyperplasia with lower urinary tract symptoms.
At a glance
| Generic name | Tamsulosine Arrow LP |
|---|---|
| Sponsor | Pierre Fabre Medicament |
| Drug class | Alpha-1A adrenergic receptor antagonist |
| Target | Alpha-1A adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | FDA-approved |
Mechanism of action
Tamsulosin selectively blocks alpha-1A adrenergic receptors located on smooth muscle cells in the prostate gland and bladder neck. By antagonizing these receptors, it reduces smooth muscle tone and tension in these tissues, thereby decreasing urinary obstruction and improving urinary symptoms associated with benign prostatic hyperplasia. The LP (long-acting) formulation provides sustained drug release for once-daily dosing.
Approved indications
- Benign prostatic hyperplasia with lower urinary tract symptoms
Common side effects
- Retrograde ejaculation
- Dizziness
- Headache
- Asthenia/fatigue
- Orthostatic hypotension
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tamsulosine Arrow LP CI brief — competitive landscape report
- Tamsulosine Arrow LP updates RSS · CI watch RSS
- Pierre Fabre Medicament portfolio CI